At some point in their lives, 5 to 12 per­cent of Amer­i­can men and 10–25 per­cent of women will suf­fer an episode of depres­sion, mak­ing it the most com­mon­ly diag­nosed men­tal dis­or­der today. Unlike nor­mal sad­ness, which pass­es with time, depres­sion feels unstop­pable and caus­es peo­ple to lose inter­est in near­ly all activ­i­ties. Because it affects a person’s abil­i­ty to eat, sleep, work, and func­tion nor­mal­ly, it exacts a huge cost on the econ­o­my, esti­mat­ed at $30 bil­lion dol­lars annu­al­ly. The cost in human suf­fer­ing can­not be mea­sured.

Mil­lions of peo­ple diag­nosed with depres­sion turn to med­ica­tion as a treat­ment, and many of the most pop­u­lar depres­sion med­ica­tions Prozac, Zoloft, and Pax­il, to name a few work by chang­ing the chem­istry of the brain, increas­ing or decreas­ing the speed of infor­ma­tion exchanged between cells. How they alle­vi­ate depres­sion is not well under­stood, but the drugs are wide­ly pre­scribed and, accord­ing to some experts, not always for good rea­son.

“Most peo­ple who are depressed go to their MD’s and are pre­scribed med­ica­tion, which is easy to take and usu­al­ly well-tol­er­at­ed,” says Helen May­berg, an Emory Uni­ver­si­ty neu­rol­o­gist. “But only about 30 per­cent of peo­ple who take meds get bet­ter. Why?”

May­berg believes the answer may lie in her research. For years, May­berg has stud­ied how neur­al path­ways are dis­rupt­ed dur­ing men­tal ill­ness, espe­cial­ly depres­sion. Using the newest scan­ning tech­nolo­gies, she is mak­ing ground­break­ing dis­cov­er­ies about how depres­sion is wired in the brain and she is devel­op­ing a new tech­nol­o­gy that can lit­er­al­ly “rewire” the brain to over­come depres­sion. If suc­cess­ful, her exper­i­ments could rev­o­lu­tion­ize the field of depres­sion treat­ment.

Explor­ing Area 25

May­berg first became inter­est­ed in brain scan­ning and depres­sion when she was a research fel­low at Johns Hop­kins Uni­ver­si­ty in the mid-1980s. There, she stud­ied stroke vic­tims and patients with Parkinson’s and Huntington’s dis­eases all of whom are at high­er risk for depres­sion and dis­cov­ered some­thing inter­est­ing: Brain scans of depressed patients dis­played a unique activ­i­ty pat­tern. The frontal lobes of the brain the parts asso­ci­at­ed with high­er cog­ni­tive process­es, like how we inter­pret our expe­ri­ences and emo­tions always dis­played low­er activ­i­ty lev­els. They didn’t in non-depressed patients.

“It made us real­ize that depres­sion is not nec­es­sar­i­ly due to a chem­i­cal imbal­ance, as peo­ple have thought for years, but might be due to a wiring pat­tern in the brain that has gone wrong,” says May­berg. Build­ing on this insight, May­berg has spent her career try­ing to learn more about the wiring of the depressed brain. Using scan­ning tech­niques, she’s stud­ied how brain activ­i­ty changes before and after treat­ment. In one line of research, May­berg found that depressed patients who improved after tak­ing Prozac for six weeks showed increased activ­i­ty in their frontal lobes, again sug­gest­ing this region plays a role in depres­sion. But she also made anoth­er, unex­pect­ed dis­cov­ery: Activ­i­ty in the sub­gen­u­al cin­gu­late a band of brain tis­sue known as “Area 25” that lies deep with­in the frontal cor­tex and is part of the emo­tion con­trol cen­ter of the brain went down in all the patients who recov­ered.

May­berg won­dered whether there might be a spe­cif­ic kind of inter­ac­tion between these brain regions that led to depres­sion. She spec­u­lat­ed that a high lev­el of activ­i­ty in Area 25 might depress activ­i­ty in the frontal lobes, which would pre­vent the frontal lobes from reg­u­lat­ing the dis­tress­ing thoughts that con­tribute to depres­sion. But lat­er she stud­ied patients who had recov­ered from depres­sion using cog­ni­tive behav­ioral ther­a­py (CBT), a form of talk ther­a­py where patients are taught how to iden­ti­fy neg­a­tive think­ing pat­terns and replace them with more pos­i­tive ones. In that study, patients who recov­ered had com­plete­ly dif­fer­ent results: Activ­i­ty went down in the frontal lobes instead of up, and activ­i­ty in Area 25 did not change.

These two seem­ing­ly con­tra­dic­to­ry results sug­gest­ed to May­berg that depres­sion is not caused by a sin­gle brain activ­i­ty pat­tern, but by a brain activ­i­ty pat­tern that is dif­fer­ent for dif­fer­ent patients. Area 25 and the frontal lobes, she thought, form an inter­ac­tive cir­cuit in the brain, work­ing togeth­er to mod­u­late mood; in depressed patients, parts of the cir­cuit are either over-active or under-active. Med­ica­tion and CBT both appear to work by cor­rect­ing the bal­ance between the frontal lobes and Area 25: Med­ica­tion tar­gets Area 25 so that it doesn’t inhib­it the frontal lobes, where­as CBT tar­gets the frontal lobes direct­ly, mak­ing them less active. The impli­ca­tion to May­berg was that dif­fer­ent patients would require dif­fer­ent treat­ments, depend­ing on their par­tic­u­lar brain cir­cuit­ry.

These con­clu­sions are bol­stered by numer­ous stud­ies of treat­ment effec­tive­ness, accord­ing to Steve Hol­lon, a pro­fes­sor at Van­der­bilt Uni­ver­si­ty and an expert in the field of depres­sion research. The com­bi­na­tion of CBT and med­ica­tion, explains Hol­lon, is con­sid­ered the most effec­tive treat­ment for depres­sion to date, and this mix of treat­ments has proven to be bet­ter at alle­vi­at­ing depres­sion than either treat­ment alone. If each treat­ment affects the brain dif­fer­ent­ly as Mayberg’s work sug­gests it fol­lows that the com­bined treat­ment would have the best chance of induc­ing recov­ery for the great­est num­ber of patients because it would help those who would ben­e­fit from one or the oth­er treat­ment, as well as patients who might respond best to a mix­ture of the two.

“Mayberg’s research is help­ing iden­ti­fy for us what is going on in depres­sion at the neur­al lev­el, how CBT and med­ica­tion affect the brain,” says Hol­lon. “She’s real­ly on the cut­ting edge of where the field of depres­sion research needs to go.”

Rad­i­cal recov­er­ies

May­berg moved to Emory Uni­ver­si­ty in 2003, where she is now work­ing with patients she calls the “ter­mi­nal­ly depressed” those who’ve gone through mul­ti­ple treat­ment approach­es and still haven’t recov­ered. In one recent, trail­blaz­ing study, she took six ter­mi­nal­ly depressed patients and, using a new tech­nol­o­gy called “deep brain stim­u­la­tion” (DBS), embed­ded wires in their brains at Area 25. The wires were attached to a bat­tery, which act­ed like a pace­mak­er, deliv­er­ing a steady but adjustable cur­rent to the wire. Imme­di­ate­ly, patients report­ed some relief from their symp­toms, and their symp­toms con­tin­ued to improve over the weeks that fol­lowed.

“Four patients 60 per­cent recov­ered from their depres­sion. It was incred­i­ble,” says May­berg. “These are peo­ple who’d suf­fered for years, whose depres­sion was con­sid­ered intractable.” After a few months, May­berg also saw activ­i­ty increase in their frontal lobes, sug­gest­ing that stim­u­la­tion to Area 25 helped restore bal­ance to their brains’ cir­cuit­ry. Four years lat­er, those four patients still have their wires intact and are still in remis­sion. Most have either stopped using med­ica­tion or have great­ly reduced their dosage. Accord­ing to May­berg, their new chal­lenge is to learn how to adjust to being healthy. “Now they need to know what it’s like to have a bad day. Before, every day was a bad day,” she says.

As impres­sive as these results are, DBS is clear­ly not for every­one. May­berg offered it to peo­ple who, unlike most depressed patients, had not improved after years of try­ing oth­er, more con­ven­tion­al treat­ments. And of course, even among peo­ple who might ben­e­fit from DBS when all oth­er options fail, many will resist such an inva­sive treat­ment. Hus­sei­ni Man­ji, a neu­ro­sci­en­tist and the direc­tor of the Nation­al Insti­tute of Men­tal Health’s Anx­i­ety and Mood Dis­or­ders Pro­gram, says that while he sees Mayberg’s DBS results as promis­ing, he ques­tions the prac­ti­cal­i­ty of imbed­ding elec­trodes in patients’ brains. “She has helped nar­row down where we need to inter­vene in the depressed brain,” says Man­ji. “But wouldn’t it be ide­al if we could do the same thing chem­i­cal­ly, to avoid brain surgery?”

Still, Man­ji com­mends May­berg for mak­ing impor­tant con­tri­bu­tions to the sci­en­tif­ic under­stand­ing and treat­ment of depres­sion. Like May­berg, he thinks that brain scans could help iden­ti­fy sub­groups of peo­ple who would ben­e­fit from cer­tain forms of treat­ment, espe­cial­ly if these treat­ments are used in com­bi­na­tion with one anoth­er. “It may be that one needs chem­i­cal treat­ments to bring one­self back to a time when the brain wiring went wrong, and then cog­ni­tive restruc­tur­ing to rewire the brain so that it can fol­low a more pos­i­tive path­way,” he says.

At the Nation­al Insti­tute of Men­tal Health, Man­ji and a team of researchers are busy try­ing to devel­op chem­i­cal treat­ments that would work more effi­cient­ly than what’s cur­rent­ly on the mar­ket. They are search­ing for a “smart mol­e­cule,” a chem­i­cal that would more accu­rate­ly tar­get the parts of the brain impli­cat­ed in depres­sion. So far, they’ve had luck with ket­a­mine, a med­ica­tion that, in high­er dos­es, can be used as an anes­thet­ic. In a study he con­duct­ed with ter­mi­nal­ly depressed patients, pub­lished in 2006, 71 per­cent of those patients receiv­ing a sin­gle intra­venous dose of ket­a­mine showed improve­ment with­in one day. This com­pares favor­ably against cur­rent pop­u­lar depres­sion med­ica­tions, which tend to take weeks to work. But ket­a­mine has severe side-effects, includ­ing hal­lu­ci­na­tions, which makes it unten­able as a med­ica­tion for the gen­er­al pub­lic. Still, Man­ji believes that its fast action shows that researchers are on the right track.

“Cur­rent med­ica­tions may be work­ing at an indi­rect mol­e­c­u­lar tar­get in the brain, which is why there is such a lag time,” says Man­ji. “We need to move 20 steps beyond, to tar­get the exact cir­cuit in the brain that’s caus­ing depres­sion.”

Hol­lon agrees that med­ica­tion for depres­sion needs to be refined. “Cur­rent­ly, we put peo­ple with depres­sion on med­ica­tion and usu­al­ly keep them there,” he says. “But what we don’t know and we need to know is who needs to stay on med­ica­tion and who can come off of it.” Hol­lon hopes that Mayberg’s research will improve under­stand­ing of what is hap­pen­ing to patients’ brains as they progress through the heal­ing process, so that psy­chol­o­gists can select not only the best course for treat­ment, but the best treat­ment over time.

Get­ting there

Mean­while, May­berg is busy recruit­ing more patients to do anoth­er DBS study. She is also involved in a large-scale project to see whether brain scans of depressed patients can be used to pre­dict the best treat­ment for those patients. If suc­cess­ful, her exper­i­ments could trans­form depres­sion treat­ment. “If we knew that a par­tic­u­lar brain pat­tern indi­cat­ed what type of treat­ment a patient would best respond to, it could save them years of unsuc­cess­ful treat­ment,” says May­berg. It could also elim­i­nate the need for drug treat­ment for some patients, and help those who resist med­ica­tion because of per­son­al beliefs or adverse side effects, she adds.

Despite these advances, May­berg says the research has a long way to go.

“We can’t be so arro­gant that we think we know exact­ly what a pat­tern of activ­i­ty in the brain means,” says May­berg. “When I see Area 25 light up because the per­son is sad, I still don’t know if that’s gen­er­at­ing the sad­ness, or if that’s the sig­nal try­ing to turn off the sad­ness.” She hopes that 10 years from now, bet­ter tech­nol­o­gy will enable sci­en­tists to uncov­er more spe­cif­ic infor­ma­tion about the neur­al cir­cuit­ry of depres­sion and oth­er men­tal dis­or­ders, and that future treat­ment approach­es will involve tar­get­ing spe­cif­ic areas of the brain rather than flood­ing it with non­spe­cif­ic drugs, like Prozac.

In the mean­time, May­berg is cau­tious­ly opti­mistic. “We need to move away from a one-size-fits-all approach to men­tal ill­ness,” she says. “I think we’re get­ting there.”

— Jill Sut­tie, Psy.D., is Greater Good’s book review edi­tor and a free­lance writer. Copy­right Greater Good. Greater Good Mag­a­zine, based at UC-Berke­ley, is a quar­ter­ly mag­a­zine that high­lights ground break­ing sci­en­tif­ic research into the roots of com­pas­sion and altru­ism.

6 Responses

Hel­lo Vivien, per­form­ing sim­i­lar activ­i­ties typ­i­cal­ly acti­vate sim­i­lar brain areas, with one caveat: when we per­form some­thing for the first time, when we are learn­ing, we tend to engage heav­i­ly parts of the frontal lobe (behind your fore­head). For exam­ple, play­ing vio­lin for the first few times would acti­vate wider parts of the brain than when it has become rou­tine.

Thank you for your com­ment. More than “plea­sure and self-help”, I’d sug­gest that it is the often too com­plex lives we tend to live that con­tribute to the high lev­els of anx­i­ety, stress and depres­sion in our soci­ety.

The bet­ter we learn how to learn, how to cope with change, how to adapt, the bet­ter we will all be.

Yes, indeed. I believe in the state­ment: Life is 10% what hap­pens to me and 90% how I react to it!

At the same time, we’ve become a busy soci­ety- dis­as­so­ci­at­ed from our neigh­bours and fam­i­ly only break­ing down com­mu­ni­ty and increas­ing our stress and iso­la­tion. With iso­la­tion comes a strug­gle to with­stand the waves of life on our own. But, we want to do things our­selves- hence, the ‘self help’ phe­nom­e­non.

One of the biggest strate­gies to defeat­ing depres­sion, accord­ing to the med­ical jour­nals, is social sup­port. With this break­ing down, it’s no won­der depres­sion seems to be on the rise.

We don’t need bet­ter drugs, we need bet­ter com­mu­ni­ty. We need com­mu­ni­ties of unselfish­ness where we put oth­ers first and ask how they are doing.

Today we have garages attached to our hous­es where we can get into our cars with­out step­ping out­side. We can dri­ve off to work and home again, often nev­er even ask­ing our neigh­bours how their day was!

(Also, notice we no longer get fresh air and exer­cise).

We come up with more gad­gets that allow us to cop out of true con­ver­sa­tion and friend­ship.

Notice, I am blog­ging with you folks who I don’t know, while my hus­band is on his com­put­er talk­ing with folks on the oth­er side of the world.

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters and more, SharpBrains is an independent market research firm tracking health and performance applications of brain science.